Joint injection evidence for the Rheumatology Portfolio Pathway: what assessors need to see

Why procedural evidence carries weight in Rheumatology Portfolio Pathway

The Rheumatology Portfolio Pathway application is built on a broad evidence base: clinic letters demonstrating diagnostic range, multi-source feedback from the MDT, biologics and DMARD governance evidence, and the GIM acute take for dual applicants. Within that evidence mix, injection and aspiration evidence occupies a distinctive place because it is directly verifiable. A DOPS entry records a named assessor observing a named procedure on a specific date; a logbook entry records the indication, the agent used, and the outcome. This specificity is what makes procedural evidence compelling.

For most senior NHS rheumatologists - Specialty Doctors, Specialist grade doctors, Associate Specialists, and non-substantive Consultants working in UK NHS posts - the injection work is happening anyway. A rheumatology Consultant running an independent clinic performs knee injections, shoulder injections, and soft tissue procedures every week. The gap is almost never clinical volume; it is the quality and completeness of what is written down about each procedure. That framing matters, because the solution to a thin procedural file is not to arrange additional injection sessions you would not otherwise do. It is to start capturing existing practice to a standard that assessors can read, evaluate, and credit.

The Portfolio Pathway is designed for doctors who are already practising at consultant level. In rheumatology, that means a doctor who selects the appropriate injection for a given clinical presentation, chooses between landmark and ultrasound guidance based on clinical judgment, adjusts the corticosteroid dose and preparation for the joint size and pathology, monitors the patient afterwards, and uses the outcome of the injection to inform the next step in management. The application asks you to demonstrate that this is what you already do. The procedural logbook is the mechanism through which that demonstration happens.

How the Rheumatology SSG frames injection and aspiration competence

The backbone of any Rheumatology Portfolio Pathway application is the GMC Specialty Specific Guidance (SSG) for Rheumatology with General Internal Medicine, read alongside the 2022 rheumatology curriculum and the internal medicine curriculum. The SSG is published by JRCPTB and the GMC, and it sets out the Capabilities in Practice (CiPs) that assessors use to evaluate your application. Procedural competence sits within the clinical management CiPs, and the SSG specifies that injection and aspiration skills must be evidenced at Level 4 - the level of unsupervised independent practice. Understanding how to read the SSG properly is covered in the separate SSG guide; this article assumes you have read it and focuses specifically on the procedural strand.

The 2022 rheumatology curriculum identifies a range of joint and soft tissue procedures that a consultant rheumatologist should be able to perform independently. The SSG translates this into evidential requirements for a Portfolio Pathway application. Specific indicative case volumes appear in the current SSG document, not in this article, because those figures are subject to periodic review by JRCPTB and the relevant Royal College; always check the live SSG on the JRCPTB website before planning your evidence collection. What this article can reliably describe is the quality standard each entry must meet - and that standard is more stable than any specific number.

The British Society for Rheumatology (BSR) has also published guidance on musculoskeletal injection and aspiration competence, and BSR resources are relevant primary source material for anyone building an injection logbook. BSR clinical guidelines on conditions where injection is a standard treatment modality - rheumatoid arthritis, osteoarthritis, crystal arthropathies - provide the clinical framework within which each injection decision sits. Linking your procedural evidence explicitly to these guidelines is one marker of consultant-level thinking.

The SSG asks assessors to evaluate not just technical procedural skill but the clinical thinking that frames each procedure. A knee injection performed because the patient had a tense haemarthrosis after a fall, with joint aspiration preceding the corticosteroid injection to confirm the absence of septic arthritis, followed by documentation of the aspiration findings and the subsequent clinical decision, is a qualitatively different piece of evidence from a knee injection for osteoarthritis performed in a routine chronic disease clinic. Both are valid evidence; neither is wasted. But the more complex the clinical context, the more the evidence demonstrates the consultant-level judgement the SSG is looking for.

Large joint intra-articular injections: the DOPS framework

Intra-articular injection of large joints is the most commonly performed procedural skill in NHS rheumatology practice, and the knee is the joint most frequently injected across all clinical settings. Knee injections should therefore make up a substantial part of any logbook, but the logbook should not be dominated by them to the exclusion of other joint types. Assessors look at breadth as carefully as volume. A logbook that shows 40 knee injections but no shoulder, no hip, and no small joint evidence does not demonstrate the range of procedural competence that a consultant rheumatologist requires.

The knee joint is approached either medially or laterally, at the level of the superior border of the patella, with the patient supine and the knee extended or slightly flexed depending on effusion size. Corticosteroid preparations most commonly used in UK NHS practice include methylprednisolone acetate (Depo-Medrone) and triamcinolone acetonide (Kenalog), both typically combined with a local anaesthetic - lidocaine or bupivacaine depending on the duration of anaesthesia desired. The dose is adjusted by joint size: a large knee joint takes a higher total corticosteroid dose than a small MCP joint. Document the preparation chosen, the dose, and the volume used in every entry. If you deviate from your standard preparation for a particular clinical reason - for example, using a different corticosteroid because of concerns about skin depigmentation in a patient with darker skin and a superficial soft tissue injection site - document that reasoning explicitly.

The shoulder

The shoulder presents two distinct injection targets that should both appear in the logbook: the glenohumeral joint and the subacromial bursa. These are anatomically separate and serve different clinical purposes. A glenohumeral injection is indicated for inflammatory arthritis affecting the joint itself - rheumatoid arthritis, psoriatic arthritis, or glenohumeral osteoarthritis. A subacromial injection is indicated for subacromial impingement, supraspinatus tendinopathy, and rotator cuff related pain. Documenting the distinction between these two targets in DOPS entries and logbook entries demonstrates anatomical precision and appropriate clinical reasoning.

The glenohumeral joint can be approached anteriorly (between the coracoid process and the head of humerus), posteriorly (2cm below and 2cm medial to the posterolateral angle of the acromion), or laterally. The posterior approach gives the most direct access to the joint space and is least likely to involve nearby neurovascular structures. The subacromial bursa is approached posterolaterally, directing the needle towards the undersurface of the acromion. Ultrasound guidance improves accuracy for glenohumeral injections - studies consistently show that landmark-guided glenohumeral injection has significant intra-articular failure rates compared to US-guided injection. For a Portfolio Pathway applicant who performs glenohumeral injections without ultrasound guidance, acknowledging this in the logbook notes and documenting any clinical feedback that suggests the injection reached or did not reach the intended target (for example, a diagnostic LA block that did or did not give temporary pain relief) shows an awareness of technique limitations that reflects consultant-level thinking.

The hip

The hip joint is a deep joint, and accurate intra-articular injection by landmark technique alone has a low success rate. Most UK NHS rheumatology departments expect hip joint injections to be performed under ultrasound or fluoroscopic guidance. If your logbook includes hip injections performed as landmark injections, this should be noted alongside any clinical evidence of intra-articular placement (for example, a diagnostic LA block that produced pain relief consistent with intra-articular pathology). For most applicants, hip joint injection is where demonstrating access to image guidance becomes most clinically relevant and most clearly evidenced.

For Portfolio Pathway purposes, the critical point is that your logbook accurately reflects the technique used. Accurate documentation of technique - including the honest acknowledgement that image guidance was or was not used - is a marker of the trustworthy record-keeping that assessors expect at consultant level.

Small joint and soft tissue injections

Small joint injection and soft tissue injection are where many rheumatology injection logbooks are weakest, because these procedures happen in the background of a clinic rather than in a dedicated procedure session. A metacarpophalangeal (MCP) injection for a patient with active rheumatoid synovitis, a trigger finger injection for flexor tendon sheath inflammation, or a de Quervain injection for first extensor compartment tenosynovitis - these are done quickly, the patient is grateful, and the encounter is rarely formally documented to the standard a Portfolio Pathway logbook requires. That is the gap this section addresses.

Small joint injections - MCP, PIP, DIP, metatarsophalangeal (MTP) - require specific anatomical knowledge because the joint space is narrow, the needle must be placed accurately without entering adjacent tendon or ligament, and the volume injected is small (typically 0.3-0.5ml, sometimes less). The clinical indication is usually active inflammatory synovitis in a patient whose systemic DMARD or biologic is being titrated, or whose disease has broken through existing therapy at a single joint while the rest of the disease is controlled. That clinical context - bridging therapy for a patient awaiting biologic escalation, or managing a single joint flare in an otherwise well-controlled patient - should be documented explicitly. It links the procedural evidence to the broader DMARD and biologics governance evidence that runs through the rest of the application.

Soft tissue injections cover a range of periarticular structures that a consultant rheumatologist manages independently:

• De Quervain tenosynovitis (first extensor compartment, extensor pollicis brevis and abductor pollicis longus): approached along the first dorsal compartment of the wrist, directing the needle into the tendon sheath rather than the tendon itself. This is technically demanding and has a higher failure rate than large joint injections when performed without image guidance; document whether ultrasound was used and, if not, what clinical feedback suggested the sheath was entered (for example, flow of injectate without resistance).
• Trigger finger (flexor tendon sheath inflammation at the level of the A1 pulley): injected at the MCP crease, directing the needle along the tendon sheath. Clinical success at follow-up - resolution of triggering and tenderness - is the best evidence of accurate placement and should be documented.
• Subacromial bursa: covered above under the shoulder; document the indication separately from any glenohumeral injection in the same patient.
• Trochanteric bursa: injected at the point of maximal tenderness over the greater trochanter, with the patient lateral decubitus. The clinical diagnosis of trochanteric bursitis versus gluteal tendinopathy versus referred lumbar pain should be documented, because this distinction affects both the injection target and the prognosis of injection treatment.
• Olecranon bursa: aspirated and, where appropriate, injected for non-septic olecranon bursitis. This is also an important diagnostic site - olecranon bursal fluid should be sent for cell count, crystals, and culture in any case where infection has not been clinically excluded.

Joint aspiration and synovial fluid analysis

Joint aspiration is a distinct and high-value evidence category within the procedural logbook, because it bridges the technical skill of joint access with the clinical skill of diagnostic interpretation. A knee aspiration performed in the emergency assessment unit on a patient with a hot, swollen joint - where septic arthritis must be excluded before any other diagnosis is entertained - demonstrates a qualitatively different level of clinical responsibility than an elective injection in a chronic disease clinic. Both count; the diagnostic aspiration carries more evidential weight per entry.

Synovial fluid analysis should be documented in full for every diagnostic aspiration. The key parameters are: appearance (clear, turbid, haemorrhagic, purulent - the colour and turbidity are clinical data, not just descriptions), viscosity (a sign of fluid quality), cell count and differential if available, crystal examination under polarised light (needle-shaped negatively birefringent crystals for monosodium urate in gout; rhomboid positively birefringent crystals for calcium pyrophosphate in pseudogout), Gram stain, and culture and sensitivity. Not every aspiration will yield diagnostic fluid, but the effort to analyse it and the results obtained should be documented whether they are positive or negative. A dry tap on a clinically hot, swollen joint, particularly in a patient with risk factors for septic arthritis, is itself a clinical decision point: it does not exclude infection, and the decision to proceed to empirical antibiotics or to re-attempt aspiration should be documented as a clinical decision with a rationale.

Therapeutic aspiration - removing synovial fluid to reduce pain and improve joint function in a large tense effusion - is simpler in evidential terms but should still be documented with a clear indication, the volume removed, the patient's symptomatic response, and the plan. For recurrent tense effusions, document why repeat aspiration was chosen over other management options (for example, referral for surgical review in a patient with osteoarthritis awaiting arthroplasty). The clinical decision-making around the choice of aspiration, injection, or both in the same procedure should be explicit.

The olecranon bursa merits separate note as an aspiration site. Olecranon bursitis has a differential that includes septic bursitis, gout, CPPD, rheumatoid nodule, and simple non-inflammatory bursitis; aspiration and fluid analysis is diagnostic. Given the proximity of the olecranon bursa to the skin and the risk of introducing infection with injections near the joint, post-aspiration injection of the bursa with corticosteroid should be documented with a specific note about the decision to inject after infection was excluded by fluid analysis, rather than at the time of the aspiration before culture results are available.

Ultrasound-guided procedures: documenting image-guided competence

Musculoskeletal ultrasound (MSUS) has become a standard tool in NHS rheumatology practice, supporting both diagnosis (synovitis grading, enthesitis assessment, tendon pathology) and treatment (image-guided injection). The BSR has developed a training pathway for rheumatologists wishing to develop MSUS competence, and MSUS training is increasingly embedded in UK rheumatology training programmes. For Portfolio Pathway applicants, the first question is not whether MSUS is required but whether you perform it, and if so how to evidence both the training element and the clinical practice element.

If you perform MSUS-guided procedures, the evidence requirement divides into two components. First, the training record: a recognised MSUS training course or structured local training programme with documented assessment of competence. Second, the clinical logbook: a record of MSUS-guided procedures performed independently, separate from the general injection logbook, that shows the range of structures guided and the clinical context for each guided procedure. The logbook entry should note that the procedure was image-guided, identify the ultrasound probe and machine used where relevant, and record the sonographic findings that informed needle placement - for example, identifying an effusion before confirming needle tip position in joint, or confirming intra-tendon sheath needle position by visualising injectate flow within the sheath.

If you do not have access to MSUS or have not completed formal MSUS training, this should not be presented as a gap that needs to be hidden. Instead, document clearly which of your procedures used landmark technique and which were image-guided, where image guidance was or was not available. For joints where landmark technique has poor accuracy - the hip joint in particular - document why image guidance was not used and what clinical evidence you have of intra-articular placement. The honest, accurate record of what you can and cannot do is itself a marker of consultant-level professionalism; it is better evidential practice than a logbook that either omits difficult cases or implicitly claims more image guidance competence than you have.

For applicants who do have MSUS training, the evidence of MSUS-guided procedures is an additional positive in the logbook, not a separate requirement. Assessors evaluating a Rheumatology Portfolio Pathway application will note image-guided entries as demonstrating higher technical competence for appropriate cases; they will not penalise landmark technique for procedures where landmark injection is standard practice and reliable (large knee joint injections, subacromial bursal injections from a posterolateral approach, trochanteric bursal injections).

Mapping injection evidence to the four GMC domains

Every piece of Portfolio Pathway evidence must map to the four GMC domains. Injection evidence generates material across all four domains when documented properly, but many applicants present it only as Domain 1 (clinical skills) evidence. Making the cross-domain mapping explicit in a structured presentation of the procedural logbook is one of the most effective ways to extract full evidential value from work that has already been done.

The audit strand is particularly valuable as Domain 2 evidence within the procedural logbook. An audit of your own injection outcomes - patient-reported pain relief at four to six weeks, rate of post-injection complications, proportion of diagnostic aspirations that yielded diagnostic fluid - is a natural extension of good procedural record-keeping. A formal closed-loop audit of injection outcomes, particularly one that led to a change in practice (for example, identifying that a significant proportion of shoulder injections performed without image guidance did not produce clinical relief, and subsequently arranging access to MSUS guidance), demonstrates exactly the quality improvement thinking that the Portfolio Pathway values. An audit that produces a reflection that was subsequently acted on is more evidentially effective than one that exists only on paper.

The teaching and leadership elements of the procedural logbook are easy to overlook. If you teach junior colleagues or rheumatology trainees injection technique, if you have organised a departmental injection training session, if you have been involved in developing a local injection guideline - all of these contribute to teaching evidence and leadership evidence that maps to Domains 3 and 4, built directly from the injection work you already do.

Thin versus convincing injection logbook entries

The procedural logbook for a Rheumatology Portfolio Pathway application is evaluated entry by entry as well as in aggregate. An assessor reading a logbook of 50 entries that are each two lines long gains far less confidence in the applicant's independent practice than a logbook of 30 entries each documented to the full clinical standard. Quantity of entries matters; quality per entry matters more. The section below makes the contrast concrete.

The most common pattern in thin logbooks is that the entry records the technical act but not the clinical decision. "Right knee injection. Depo-Medrone 40mg, 1ml lignocaine." This documents that something was done; it does not document why it was done, whether it should have been done, what the intention was, or whether it worked. An assessor reading this entry learns nothing about the applicant's clinical reasoning. That is the gap.

The six-step approach above applies to every injection type in the logbook - large joint, small joint, soft tissue, and aspiration. The level of detail required for each step scales with the complexity of the case; a straightforward knee injection in a patient with known RA and a predictable response needs less documentation than a diagnostic aspiration in a patient where the fluid results changed the diagnosis. But every entry needs at least a brief response to each of the six questions.

A practical note on timing: the best logbook entries are written on the day of the procedure, or within 24 hours, while the clinical details are current. Logbooks reconstructed retrospectively from clinic letters several months later are detectable as such by assessors, because the clinical context lacks the specificity of real-time documentation. Building the documentation habit as a real-time practice, rather than as a periodic data-entry task, produces a more credible and a more useful logbook.

Building a complete procedural evidence portfolio

The procedural logbook does not exist in isolation from the rest of the Rheumatology Portfolio Pathway application. It connects to the broader evidence base in several ways that are worth making explicit when organising the portfolio.

Joint injection evidence connects directly to the clinical case mix evidence built from clinic letters and WBAs. A Mini-CEX covering a new patient assessment for an inflammatory monoarthritis that led to a diagnostic aspiration and joint injection links procedural evidence, clinical reasoning evidence, and patient management evidence into a single encounter. Making these links explicit in the portfolio - cross-referencing the logbook entry to the WBA number, or the WBA to the aspiration result that changed the diagnosis - saves assessors the work of constructing the connection themselves and gives the application a coherence that individual evidence items presented in isolation cannot produce.

The reflective practice strand is a natural partner to the procedural logbook. A reflection on a case where a diagnostic aspiration revealed septic arthritis in a patient you initially thought had a crystal arthropathy flare - documenting what you noticed, why your initial diagnosis was wrong, how you managed the transition to emergency management, and what you would do differently in how you approach hot joint assessment - is compelling evidence. It demonstrates clinical honesty, diagnostic flexibility, and the kind of self-correction that consultant-level practice demands. It also maps to Domain 4 and Domain 2 simultaneously. Use the procedural cases that taught you something as reflective practice subjects; they are more valuable than reflections on cases that went exactly as expected.

The structured reports from educational supervisors and clinical supervisors should specifically address procedural competence. When briefing a referee, point them to specific entries in the procedural logbook and ask them to comment on what they observed of your injection practice: your approach to consent, your aseptic technique, your clinical decision-making around agent selection and dose, your management of any complications. A structured report that comments on procedural practice in this level of detail is far more useful to assessors than a generic commendation of clinical competence.

Multi-source feedback from physiotherapists, orthopaedic colleagues, and nursing staff who observe injection practice is also valuable evidence. A physiotherapist who sends patients for injection and then sees them in follow-up is well placed to comment on injection outcomes. An orthopaedic colleague who sometimes co-manages patients with joint disease can comment on the appropriateness of injection decisions. MSF from the injection context, rather than only from the ward or outpatient clinic, adds a dimension to the feedback portfolio that assessors notice positively.

For the five-year rule, the procedural logbook should reflect practice within the five-year window before submission. Evidence of a high injection volume five years ago that has not been maintained in recent practice carries less weight than a smaller but consistent and current logbook. If your injection volume has reduced in a recent post because of a change in job plan, document that context in the logbook notes and ensure that you have taken steps to maintain procedural exposure - supernumerary sessions, visits to a neighbouring unit, or a structured local arrangement - rather than allowing a gap to develop that assessors must interpret from silence.

When planning the overall structure of the procedural evidence portfolio, three principles should guide the organisation. First, breadth before depth: ensure that every major joint type and at least two to three soft tissue sites are represented in the logbook before adding additional entries for high-volume procedures. Second, quality over quantity: twenty well-documented entries are more useful than sixty thin ones. Third, integration: procedural evidence that is cross-referenced to WBAs, reflections, and structured reports coheres as a body of evidence in a way that a standalone logbook does not. The application walkthrough covers how to present integrated evidence at submission.

For international doctors building procedural evidence from overseas practice before moving into a UK post, the guide on translating overseas evidence covers the general framework. The key challenge for injection evidence specifically is that corticosteroid preparations, dosing conventions, and the clinical governance around injection practice differ between healthcare systems. Where overseas entries use preparations or doses that differ from NHS standard practice, a brief annotation in the logbook acknowledging this and explaining the clinical equivalence is better practice than leaving assessors to query it. Evidence of current UK-based injection practice, even if supplementing rather than replacing overseas evidence, is strongly advisable for applicants whose logbook is predominantly from outside the UK.

The costs guide covers the GMC application fee and associated expenses. The CV format guide covers how procedural competencies should be listed in the structured CV that accompanies the application. The patient feedback strand can include feedback specifically from injection patients, which is easy to arrange and gives assessors additional insight into how the patient-facing aspects of procedural practice are managed.

All 18 specialisms

Joint injection evidence sits within the broader Rheumatology Portfolio Pathway. The guides below cover all eighteen target specialisms covered on this site, including the Rheumatology complete guide and the previous procedural deep-dive in this series covering Dermatology procedures and biopsies.